Streetwise Reports' Article Archives — Current Month (32)
Inovio Pharmaceuticals' shares rose 30%, setting a new 52-week high price, after the firm reported it received a grant of up to $9 million to develop a vaccine against the coronavirus.
The company continues to evolve this digital offering as well.
The product contains the firm's OxC-beta™ supplement.
Imaging System Developer Outlines Plan for 2020 (01/24/2020)
The company continues to advance its device toward commercialization.
Technical analyst Clive Maund examines this potential of the company's stock.
Online medical exchange operator eHealth Inc.'s shares traded higher after the firm reported preliminary financial results for Q4/19 and FY/19. The company advised that both quarterly and annual revenues exceeded prior estimates.
Molecular diagnostics company Co-Diagnostics' shares opened more than 144% higher after the firm reported it has designed a test for virus detection of the new coronavirus, 2019-nCoV, using its CoPrimer™ platform.
Neurotrope's shares traded higher today after reporting results from its Phase 2 "203" clinical trial of Byrostatin-1 for treatment of moderately severe to severe Alzheimer's patients. The firm has also been awarded a $2.7 million grant from the National Institutes of Health to conduct additional clinical research for patients with advanced Alzheimer's disease.
Biopharma Shows 'Good Start to 2020 News Flow' (01/21/2020)
The two developments that already took place this year are addressed in an H.C. Wainwright & Co. report.
Genprex's shares spiked 380% higher in morning trading as the company reported that the FDA granted Fast Track Designation for its Oncoprex immunogene therapy in combination with EGFR inhibitor osimertinib.
InMed Pharmaceuticals shares traded 25% higher after reporting that it is the first to advance cannabinol into therapeutic clinical trials.
Shares of NantKwest Inc. spiked as much as 85% higher in mid-morning trading setting a new 52-week high price after the company reported a series of positive results at the 38th J.P. Morgan Healthcare Conference in San Francisco. The firm reported that complete responses were noted in as many as six different multiple tumor types when "natural killer" cells and T cells are activated simultaneously.
Details of the arrangement and an update on the company's pipeline are provided in a Dawson James report.
Chris Temple, editor and publisher of The National Investor, explains why he recommends this small-cap as a Buy.
The disruptive technology is 'poised to deliver significant advancement in bladder cancer detection.'
The transaction brings numerous existing partnerships and digital technologies.
Shares of Transenterix opened 50% higher after the company reported that it has submitted a 510(k) submission to the FDA for the first machine vision system for use in robotic surgery.
Shares of Adaptimmune Therapeutics more than tripled in value after the company reported that its SPEAR T-cell platform delivered positive initial responses in four different solid tumor indications.
Telemedicine Tech Firm Garners Five New US Clients (01/10/2020)
With these contracts, the company extends its geographic footprint to an additional county.
Life Sciences Firm Upgrades to OTCQB Venture Market (01/10/2020)
This is a significant achievement of this developing company.
In doing so, it gets one step closer to market approval from U.S. regulators.
Rare disease biopharmaceutical company Ultragenyx Pharmaceutical's shares traded 30% higher after the firm reported positive topline results from Cohorts 2 and 3 in its Phase 1/2 study of DTX301 gene therapy in Ornithine Transcarbamylase Deficiency.
Shares of Applied Genetic Technologies skyrocketed to a new 52-week high price after the company reported positive six-month data from its ongoing Phase 1/2 clinical study for treatment in X-Linked Retinitis Pigmentosa. The firm stated that the trial data suggests durable and meaningful improvements in central visual sensitivity and advised that it plans to initiate a pivotal trial by year-end 2020.
The near-term events expected to trigger movement of the biotech's share price are outlined in a ROTH Capital Partners report.
Applied Therapeutics' shares traded 25% higher today after the company reported positive topline results from its Pivotal Phase 2 ACTION Study of AT-007 for use in the treatment of galactosemia. The firm expects to file for regulatory approval of AT-007 in H2/20.
Shares of Apellis Pharmaceuticals opened 35% higher and established a new 52-week intraday high price today after the company announced positive top-line results from its Phase 3 head-to-head study of Pegcetacoplan (APL-2) versus Eculizumab in patients with Paroxysmal Nocturnal Hemoglobinuria.
aTyr Pharma's shares traded 45% higher today after the firm reported that it had entered into a collaboration agreement with Kyorin Pharmaceutical for development and commercialization of its ATYR1923 drug in Japan.
These topline data and next steps for the therapeutic are reviewed in a Ladenburg Thalmann report.
The design of and an opinion on the included studies are provided in an H.C. Wainwright & Co. report.
The company, however, will continue to advance the same therapeutic in two other diseases.
Shares of Leap Therapeutics jumped 60% after the company reported that it signed an exclusive option and license agreement for its immuno-oncology drug DKN-01 with BeiGene in the Asia Pacific region excluding Japan. The firm also secured an additional $27 million in equity financing from BeiGene and two other investment groups.
Pulmatrix's shares opened 90% higher today after the firm reported that it has signed a kinase inhibitor licensing agreement with the Lung Cancer Initiative at Johnson & Johnson.
|"From a stock perspective, 2019 was a clear breakout year for DRRX."|